
zzso subcutaneous zzso human zzso zzso factor zzso zzso was administered to 40 cancer patients (17 men, 23 zzso enrolled from two medical centers to verify its clinical effectiveness and zzso The patients' mean age was zzso zzso zzso zzso In this study, there were 20 patients with zzso lymphoma, 10 with breast cancer and 10 with various other solid zzso The patients first received a course of chemotherapy without zzso zzso zzso All patients had at least one episode of zzso or zzso during the control zzso zzso (2 zzso was given zzso for 10 days during the study cycle starting on the fourth day of zzso The zzso of absolute zzso counts zzso were zzso zzso zzso zzso zzso and zzso zzso zzso zzso zzso for the zzso cycle and zzso control cycle, zzso The number of days of zzso zzso 1 zzso zzso were zzso zzso zzso and zzso zzso zzso for zzso and control cycles, zzso The duration from zzso to recovery of zzso zzso or zzso 2 zzso zzso was zzso zzso zzso days in the zzso cycle, vs zzso zzso zzso days in the control cycle zzso zzso zzso No patient withdrew from the zzso zzso events were mild, with zzso to zzso of patients developing zzso general zzso back pain, anorexia or zzso These zzso were tolerable in all zzso The zzso abnormalities were subtle and zzso zzso 2 zzso given zzso for 10 days beginning on the fourth day of chemotherapy is very effective zzso safe and zzso 

